Sistemic announces companion biomarker programme

Published: 4-Jul-2011
Research & Development

Extends miRNA drug discovery toolkit

Sistemic, a global company with expertise in microRNA, has released a new companion biomarker programme, which extends its SistemRNA suite of drug discovery and development tools.

The firm, based in Glasgow in Scotland and Boston, US, says this programme simplifies the benefits of miRNA analysis and profiling to support timely decision making within clinical research. The new multiple miRNA biomarkers can be used to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.

Companion biomarkers are the most recent extension of microRNA technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies.

The firm says the system will use miRNA to identify highly discriminatory biomarkers, which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.

See more

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Read more
Cell therapy companies to be offered a streamlined process for clinical trials

Trending Articles

  1. Orion secures exclusive license to Abzena’s CHAb-designed oncology antibody The deal strengthens Orion’s cancer R&D pipeline with a de-risked monoclonal antibody developed using Abzena’s proprietary Composite Human Antibody (CHAb) and AbZelectPRO platforms
  2. Aenova expands sterile fill & finish manufacturing at its Latina site New line to boost biologics capacity and support a wide range of container formats
  3. GemPharmatech and MSK to enter antibody research collaboration The Memorial Sloan Kettering Cancer Center (MSK) will use GemPharmatech's antibody discovery platform to accelerate the development of next-generation cancer therapies
  4. Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
  5. Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Cell therapy companies to be offered a streamlined process for clinical trials
Research & Development

Sistemic cuts cost of drug discovery

Launches microRNA technology to filter out harmful compounds early in development process
Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster
Research & Development

Piramal Pharma Solutions formalises partnership with IntoCell

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field
Research & Development

Immunology CRO reports shift to autoimmunity projects

RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends
Research & Development

Merck partners with Promega to advance 3D cell drug discovery technologies

Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Subscribe now